IFNB1 and myeloid sarcoma: Comparing the treatment efficacy between etomoxir and IFN-β (the first line of medicine given currently to MS patients) showed that IFN-β treatment was ineffective at 1 or 5 days after induction of the disease in animals with EAE, whereas etomoxir had very pronounced efficacy by significantly lowering the clinical scores of the animals compared to animals receiving IFN-β day 1 and 5, and placebo (Fig 4a).